DOD Translational Team Science Award, a new grant, funded!
We will determine if we can predict the ability of pyrvinium to reprogram the gastric mucosa using patient-derived pre-cancer organoids. Also, we will initiate a clinical trial to evaluate the ability of a 2-week treatment with pyrvinium to reprogram metaplasia in a high-risk diverse population at Duke University in North Carolina.
Grant funds research for therapies to prevent stomach cancer
Leave a Response